Alamar Biosciences Enhances NULISAseq Panel for CNS Diseases
Alamar Biosciences, a leader in precision proteomics, has taken an ambitious step forward in the battle against neurodegenerative diseases. On May 15, 2025, the company announced a significant expansion of its renowned NULISAseq™ CNS Disease Panel, now featuring groundbreaking blood tests for multiple brain-derived phosphorylated tau proteins. This panel is set to revolutionize the early detection and understanding of diseases such as Alzheimer's and other tauopathies.
A New Milestone in Neurodegenerative Disease Research
The upgraded NULISAseq panel now includes assessments for pTau217, pTau181, pTau231, and total tau (tTau) proteins. These metrics are extracted directly from blood samples, achieving unprecedented sensitivity and specificity essential for researching neurodegenerative disorders. This pivotal expansion addresses a long-standing challenge in the scientific community – differentiating between peripheral tau species and brain-derived tau, significantly enhancing the diagnostic capabilities for conditions related to tau pathology.
Yuling Luo, the founder and CEO of Alamar Biosciences, emphasized the importance of this development, stating, "Scientists have long sought a reliable blood-based solution to screen for tau-related pathologies. Our enhancements to the NULISAseq Panel empower researchers to engage with the complete spectrum of tauopathies with remarkable sensitivity and cadence. This progress promises to accelerate biomarker research and facilitate drug development for Alzheimer's disease and similar disorders.”
Transformative Potential for Alzheimer's Screening
The ability to detect brain-derived pTau species through blood tests marks a transformative moment for early screening and monitoring of Alzheimer's and related conditions. According to Nicholas Ashton, Head of Neurodegenerative Disease Biomarker Research at Banner Health, “Until now, we were unable to multiplex differentiate between brain-derived pTau and peripheral pTau. Recent findings highlight the importance of being able to detect brain-derived pTau for more specific Alzheimer's screening. Alamar’s new CNS disease panel provides an unprecedented opportunity to enhance the diagnostic accuracy and clinical utility of these biomarkers, which will significantly impact patient care and clinical research.”
Commitment to Neuroscience Collaboration
Alamar Biosciences remains committed to partnering with the neuroscience community to uncover biomarkers enabling earlier diagnosis and better patient stratification and therapeutic monitoring. This dedication underscores their drive to innovate in the sphere of proteomics, paving the way for advancements in medical research.
For more information about the NULISAseq™ CNS Disease Panel and the comprehensive range of proteomic solutions offered by Alamar Biosciences, visit
www.alamarbio.com.
About Alamar Biosciences, Inc.
Founded with a vision to fortify the life sciences landscape, Alamar Biosciences specializes in precision proteomics geared towards early disease detection. Their proprietary NULISA platform, combined with the ARGO™ HT system, works in sync with the latest genomic advancements to achieve unparalleled detection sensitivity, far exceeding the current most sensitive protein detection technologies on the market today. For additional details, explore their website at
www.alamarbio.com.